NYSE · MDT
Healthcare · Medical - Devices
$87.75
Up+$0.46 (+0.52%)
Updated Oct 9, 2026, 7:58 PM
SID Score
6.0/10
Composite research score
Smart Money
35/100
Bearish
Price performance · MDT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
MDT closed at $87.75 after 21 trading sessions, down 4.22% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $85.90 | $88.475 | $85.55 | $87.75 | 105.76M |
| Oct 7, 2026 | $87.40 | $88.19 | $85.425 | $85.51 | 55.89M |
| Oct 6, 2026 | $87.97 | $88.50 | $86.445 | $87.09 | 52.14M |
| Oct 5, 2026 | $86.33 | $88.12 | $85.5276 | $87.97 | 43.69M |
| Oct 2, 2026 | $86.55 | $87.94 | $85.59 | $86.38 | 35.37M |
| Oct 1, 2026 | $85.85 | $86.84 | $85.22 | $86.44 | 29.28M |
| Sep 30, 2026 | $86.57 | $87.42 | $86.20 | $86.29 | 26.62M |
| Sep 29, 2026 | $88.83 | $89.22 | $86.3801 | $87.09 | 19.45M |
| Sep 28, 2026 | $88.315 | $89.53 | $87.52 | $89.50 | 22.55M |
| Sep 25, 2026 | $87.61 | $88.99 | $87.12 | $88.64 | 13.05M |
| Sep 24, 2026 | $89.74 | $90.28 | $88.46 | $88.51 | 10.97M |
| Sep 23, 2026 | $90.53 | $91.1456 | $88.609 | $89.30 | 10.53M |
| Sep 22, 2026 | $92.51 | $92.67 | $90.55 | $90.77 | 14.07M |
| Sep 21, 2026 | $91.50 | $92.725 | $91.50 | $91.75 | 7.31M |
| Sep 18, 2026 | $92.28 | $93.03 | $92.04 | $92.13 | 15.45M |
| Sep 17, 2026 | $92.63 | $93.43 | $92.21 | $92.77 | 10.9M |
| Sep 16, 2026 | $93.44 | $94.545 | $92.42 | $92.60 | 10.49M |
| Sep 15, 2026 | $93.69 | $94.70 | $92.73 | $93.75 | 7.15M |
| Sep 14, 2026 | $93.35 | $94.075 | $92.73 | $93.80 | 9.26M |
| Sep 11, 2026 | $93.00 | $93.00 | $90.26 | $90.96 | 5.41M |
| Sep 10, 2026 | $92.00 | $92.535 | $90.58 | $91.62 | 5.12M |
The latest Smart Investors Daily articles mentioning MDT.
Company
Market Activity
Research & News
MDT research
Company profile and research snapshot.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Sep 30, 2026 | TD Cowen | Buy | — |
| Sep 3, 2026 | UBS | Buy | — |
| Sep 2, 2026 | Truist Securities | Hold | — |
| Sep 2, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 3, 2026
Medtronic plc (NYSE:MDT) has been a bit of a slow burner. The company has a huge medical-device business and a dependable dividend, but growth has been difficult to find over the past few years. For investors, that has made Medtronic more of an income and stability play than a stock with much excitement around it. […]
Yahoo · Oct 1, 2026
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. T
Benzinga · Oct 1, 2026
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its
Yahoo · Oct 1, 2026
The regulatory authorizations come as Medtronic looks to differentiate itself in the fast-growing pulsed field ablation market targeted by rivals Abbott, Boston Scientific and J&J.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDT.
